Organovo Presents Data on Creating Stem Cell-Based Bioprinted Kidney Organoids
Organovo adapts stem-cell techniques to developing kidney tissues using its leading 3D bioprinting platform. This company has illustrated the automated production of complex kidney organoids. Hence there is a probability of future applications, including the treatment of renal disease.
“Partnerships with world-class institutions can accelerate groundbreaking work in finding cures for critical unmet disease needs and the development of implantable therapeutic tissues,” said Taylor J. Crouch, CEO, Organovo. Furthermore, their recently announced collaboration with Murdoch Children’s Research Institute (“MCRI”) and Professor Melissa Little has made progress: automating the fabrication of kidney organoids a new reality.
In fact, here is another quote from their CEO: “By combining MCRI’s proprietary approach for modeling human kidney tissue from stem cells and Organovo’s 3D bioprinting platform, we’re able to produce detailed kidney tissues. Thus, this approach is a key step toward advancing this promising technology for both drug testing and therapeutic applications. Therefore, we’re hopeful that this will be an important step along the way in treating kidney disease.”
Indeed, Organovo has developed the capacity to 3D bioprint tissues with human functionality. Besides, they are considering IND-track programs to produce its NovoTissues® to handle serious unmet medical needs, initially with an emphasis on liver disease. Moreover, the FDA approved Organovo’s program for Alpha-1-antitrypsin deficiency as an orphan drug in 2017. In addition, they are also granting access to its ExVive™ in vitro tissue platform to optimize high value drug discovery and development. Organovo’s wholly-owned subsidiary, Samsara Sciences, offers their clients with high quality human liver cells for research applications.